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1. INTRODUCTION {#irv12455-sec-0006}
===============

Influenza is an important healthcare burden in Hong Kong[1](#irv12455-bib-0001){ref-type="ref"}, [2](#irv12455-bib-0002){ref-type="ref"}, and influenza vaccination reduced laboratory‐confirmed influenza by 59% and influenza‐like illness (ILI) by 36% in healthy children.[3](#irv12455-bib-0003){ref-type="ref"} However, there are limited post‐licensure effectiveness data in Asian children. In the European sentinel surveillance networks, seasonal influenza vaccine had low‐to‐moderate effectiveness of 43% against influenza A (H3) in the early 2011/2012 season.[4](#irv12455-bib-0004){ref-type="ref"} Similar level of vaccine effectiveness (VE) was reported from 19 influenza surveillance sites in Guangzhou[5](#irv12455-bib-0005){ref-type="ref"}, supporting the need to delineate the effectiveness of seasonal influenza vaccine in children. The reported figure of laboratory‐confirmed cases underestimates true case numbers as surveillance only focused on severe cases. More than one‐third of household contacts of A(H1N1)pdm09‐infected patients who had serologic evidence of pandemic influenza were asymptomatic.[6](#irv12455-bib-0006){ref-type="ref"} Children with mild influenza infection impose a public health concern by perpetuating influenza transmission in the community. Nonetheless, there is a lack of studies that reported influenza VE in preventing asymptomatic or mildly symptomatic influenza. Our smaller local study with biweekly nasopharyngeal sampling revealed that influenza B virus was detected in 18% and 30% of asymptomatic and sick children.[7](#irv12455-bib-0007){ref-type="ref"} Influenza surveillance in prospective cohorts is thus necessary to define the full spectrum of influenza. Because of viral antigenic drift, annual estimates of influenza VE would provide important data to monitor any change in the impact of seasonal influenza vaccination program.[8](#irv12455-bib-0008){ref-type="ref"} This point was illustrated by the surge of influenza in 2014/2015 season due to mismatch between vaccine A/H3N2 strain and the new circulating A/H3N2_Switzerland strain (<http://www.chp.gov.hk/en/view_content/18632.html>).[9](#irv12455-bib-0009){ref-type="ref"} The Centre for Health Protection (CHP) of Hong Kong recommended influenza vaccine containing A/California/7/2009 A(H1N1)pdm09‐like virus, A/Switzerland/9715293/2013 (H3N2)‐like virus, and B/Phuket/3073/2013‐like virus for the 2015/16 season. This school‐based surveillance study identified the spectrum of both subclinical and clinical influenza in children and risk factors for such infections in Hong Kong preschool and school‐age children. We also aimed to report influenza VE against influenza and ILI in these two pediatric age groups.

2. MATERIALS AND METHODS {#irv12455-sec-0007}
========================

2.1. Study population {#irv12455-sec-0008}
---------------------

This prospective cohort study recruited children in two grades of kindergartens (K.1 \[\~3 years old\] and K.3 \[\~5 years old\]) and primary schools (P.2 \[\~7 years old\] and P.5 \[\~10 years old\]) in the Kowloon and New Territories Easter regions of Hong Kong that have a residing population of 300 000 children aged below 15 years according to census data in 2011. For our sampling strategy, our team generated the first randomly selected batch of 20 kindergartens and 20 primary schools from all those registered with the Education Bureau of Hong Kong Government, contacted the school principals for participation in this surveillance study, and then generated additional random batches until our target sample size of 560 children was achieved. We recruited about half of target sample size from all eligible classes of kindergartens and another half from all eligible classes of primary schools. At the study start, we contacted principals of selected kindergartens and primary schools to obtain their permission to join this study. Parents of eligible students in these schools then gave informed written consent for their children to participate in this surveillance. This study did not set any exclusion criterion for subjects in an attempt to recruit a representative study population. Based on local data[3](#irv12455-bib-0003){ref-type="ref"}, we targeted this surveillance in consecutive influenza seasons in 2014‐2015. The Joint Chinese University of Hong Kong‐New Territories East Cluster Clinical Research Ethics Committee approved this study.

2.2. Subject assessment {#irv12455-sec-0009}
-----------------------

Parents completed a questionnaire that recorded subjects' demographics, pre‐existing medical illnesses, and influenza vaccination history within 3 years. Our staff verified vaccination history against immunization cards or with responsible doctors. Subjects with the following criteria were considered vaccinated: (i) ≥14 days post‐vaccination; (ii) received two doses 28 days apart if vaccinated for the first time; or (iii) received at least one dose in a previous influenza season and one dose in the season under study.[5](#irv12455-bib-0005){ref-type="ref"} For surveillance samples, serial flocked nasopharyngeal swabs (FNPSs) were collected every 2 weeks during school visits regardless of whether subjects had respiratory symptoms. *Surveillance* samples were collected between February and June in 2014 and between January and February in 2015. We started school surveillance within 2 weeks upon announcement of the start of influenza seasons by our CHP. This active influenza surveillance could detect children with asymptomatic or mildly symptomatic infections, which provided an unbiased data on the full spectrum of influenza infections.

Our staff phoned families every 2 weeks to remind subjects about the next surveillance visits and enquire whether they had ILI defined based on modified World Health Organization (WHO) case definition (ie, fever ≥38°C *plus* two of the followings: cough, sore throat, rhinorrhea, myalgia, headache)[10](#irv12455-bib-0010){ref-type="ref"} and whether they recently received influenza vaccination. Parents were provided our contact phone number and encouraged to inform us as soon as their children developed ILI. Our team attempted to arrange illness visit for all subjects with ILI during influenza seasons in early 2014 and 2015, and those agreed to attend illness visit returned to our outpatient clinic within 48 hours of ILI onset. During these visits, our nurse collected *illness* sample and recorded clinical features and concurrent medications.

2.3. NPS collection and processing {#irv12455-sec-0010}
----------------------------------

Nasopharyngeal sample was collected using flocked swab (Copan Diagnostics, Corona, CA).[11](#irv12455-bib-0011){ref-type="ref"}, [12](#irv12455-bib-0012){ref-type="ref"} Swabs taken from both nostrils of a subject were placed in the same specimen bottle containing viral transport medium and transported within 4 hours at room temperature to virology laboratory, where swabs were discarded after vortexing for 20 seconds to release the cells. Viral transport medium was then centrifuged and the pellet resuspended in 1 mL buffered saline and stored at −80°C until analyses.

2.4. Real‐time PCR for influenza virus detection {#irv12455-sec-0011}
------------------------------------------------

Viral RNA was extracted with PureLink^®^ Viral RNA/DNA Mini Kit (Life Technologies, Waltham, MA, USA) according to manufacturer\'s instructions. RNA was eluted with 50 μL sterile RNAse‐free water and stored at −80°C before use. Influenza A and B M gene‐specific real‐time (RT)‐PCR was performed in parallel using SuperScript^®^ III Platinum^®^ One‐Step Quantitative RT‐PCR System with ROX (Life Technologies). The RT‐qPCR reaction contained 5 μL of purified RNA, 0.5 μL of SuperScript^®^ III/Platinum^®^ T*aq* Mix (Life Technologies), 12.5 μL of 2× reaction mix in a final reaction volume of 25 μL. The sequences of primers for influenza A were as follows: (FLUAM‐7F) CTT CTA ACC GAG GTC GAA ACG TA; (FLUAM‐161R) GGT GAC AGG ATT GGT CTT GTC TTT A; and (FLUAM‐49‐P4) YAK‐TCA GGC CCC CTC AAA GCC GAG‐BHQ1. The primers for influenza B included the following: (FLUBHA‐108F) AGG GGA GGT CAA TGT GAC TG; (FLUBHA‐209R) GGG CAT AGT TTC CCT CTG GT; and (FLUBHA‐165P) FAM‐TTT TGC AAA TCT CAA AGG A‐MGB. The concentrations were 0.3 μMol L^−1^ for influenza A primers and 0.24 μMol L^−1^ and 0.2 μMol L^−1^ for influenza B primers. The cycling conditions were 50°C for 30 minutes, 95°C for 2 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C or 56°C for 30 seconds, for influenza A or influenza B respectively. RNA standards were prepared using the MEGAscript^®^ T7 Transcription Kit (Life Technologies), aliquoted, and stored at −80°C. To generate the standard curve, 10‐fold serial dilutions of the RNA transcripts were performed to cover the concentration range of 10^6^‐10^1^ copies/μL of standard. Amplification, detection, and data analysis were performed with StepOnePlus^™^ Real‐Time PCR System (Life Technologies).

2.5. Typing of influenza A and B viruses {#irv12455-sec-0012}
----------------------------------------

The molecular diagnosis of influenza virus from 28 influenza A positive and 31 influenza B positive samples were based on the WHO guidelines (<http://www.who.int/csr/disease/influenza/manual_diagnosis_surveillance_influenza/en/index.html>) with slight in‐house modifications. Extracted RNA (50 ng) was subjected to reverse transcription using Superscript II (Life Technologies). For the subtyping of the influenza, primers were based on WHO guidelines which targeted the hemagglutinin gene‐specific for A(H1N1)pdm09, A/H3, B/Victoria‐lineage, and B/Yamagata‐lineage. Conventional PCR were performed using AmpliTaq Gold 360 Master Mix (Life Technologies), and the PCR products were resolved in 2% agarose gel. Samples showing expected band size after 50 amplification cycles were considered positive.

Viral load was expressed in the absolute copy numbers of influenza M gene determined from the standard curves generated from a standard plasmid with a known copy number in serial dilutions, which was included in the quantitative PCR simultaneously, as previously described.[13](#irv12455-bib-0013){ref-type="ref"} Real‐time PCR was conducted using SYBR Premix EX Taq master mix (Takara Kusatsu, Shiga, Japan), and the results were analyzed using PRISM 7900HT system (Applied Biosystems, Foster City, CA, USA).

2.6. Statistical analysis {#irv12455-sec-0013}
-------------------------

Numerical data were expressed either in mean and standard deviation (SD) or median and interquartile range (IQR) as appropriate. The occurrence of laboratory‐confirmed influenza or ILI in relation to vaccination was analyzed by logistic regression, adjusting for covariates including seasonality (month of study), subjects' age, sex, body mass index, and comorbid medical conditions. Surveillance data from all influenza seasons were combined during such analyses. Influenza VE was estimated by the "test‐negative case‐control" design according to published method.[14](#irv12455-bib-0014){ref-type="ref"} As vaccine recipients may have a greater likelihood of seeking health care should they develop infections, this analytical approach adjusts implicitly for this confounding which would otherwise bias VE. All analyses were performed two‐tailed using SPSS v.21 (Chicago, IL, USA), with 0.05 being the level of significance.

3. RESULTS {#irv12455-sec-0014}
==========

3.1. Study population {#irv12455-sec-0015}
---------------------

Five of 97 invited primary schools and 10 of 238 invited kindergartens agreed to participate. A total of 630 children aged 7.3±2.4 years were recruited, including 322 children in 2014 and 308 children in 2015. All subjects participated either in 2014 or 2015 seasons but not both. Seven subjects (one in 2014 and six in 2015) withdrew consent before FNPS collection. A total of 333 (53.5%) subjects received influenza vaccination within 3 years, with 78, 75, and 180 children being vaccinated in one, two, and 3 years, respectively.

Table [1](#irv12455-tbl-0001){ref-type="table-wrap"} summarizes the characteristics of children who provided ≥one surveillance sample. Most children recruited in 2014 provided six to seven samples and those recruited in 2015 gave two to three samples (Figure [1](#irv12455-fig-0001){ref-type="fig"}A). A total of 2633 FNPS samples were collected from 623 children. Two FNPSs were obtained from 607 (97.4%) subjects and three samples from 505 (81.1%) subjects. ILI episodes were reported by 99 subjects, consisting of 63 (26.7%) of 236 preschoolers and 36 (9.3%) of 387 school‐age children (*P*\<.001). FNPS was not obtained from these subjects because of unavailability of research staff to conduct home visit. In addition, nine illness visits were arranged for five subjects. There was no ILI outbreak in schools or reported transmission of influenza within the same classes and household of influenza‐infected children.

###### 

Demographic and clinical features of study participants in 2014 and 2015

  Parameter                                    Result                                           
  -------------------------------------------- ------------------------------------------------ ------------
  Age in years, mean±SD                        7.0±2.7[a](#irv12455-note-0003){ref-type="fn"}   7.7±2.1
  Male                                         173 (53.9)                                       162 (53.6)
  Born in Hong Kong                            257 (80.1)                                       260 (86.1)
  Paternal secondary or university education   243 (75.7)                                       232 (76.8)
  Maternal secondary or university education   248 (77.3)                                       240 (79.5)
  History of influenza vaccination                                                              
  Within 3 y                                   162 (50.5)                                       171 (56.6)
  At 25‐36 mo ago                              115 (35.8)                                       125 (41.4)
  At 13‐24 mo ago                              127 (39.6)                                       129 (42.7)
  Within 12 mo                                 134 (41.7)                                       132 (43.7)
  History of pneumococcal vaccination          148 (46.1)                                       123 (40.7)
  Asthma phenotypes                                                                             
  Wheeze ever                                  59 (18.4)                                        49 (16.2)
  Current wheeze                               40 (12.5)                                        26 (8.6)
  Asthma ever                                  21 (6.5)                                         18 (6.0)
  Rhinitis ever                                103 (32.1)                                       119 (39.4)
  Eczema ever                                  81 (25.2)                                        84 (27.8)
  Environmental exposures                                                                       
  Breastfeeding ever                           187 (58.3)                                       160 (53.0)
  Breastfeeding for 4 mo and longer            106 (33.0)                                       87 (28.8)
  Current cat/dog keeping                      25 (7.8)                                         28 (9.3)
  Current bird keeping                         3 (0.9)                                          1 (0.3)
  Current maternal smoking                     28 (8.7)                                         29 (9.6)
  Maternal smoking during infancy              11 (3.4)                                         5 (1.7)
  Maternal smoking during pregnancy            9 (2.8)[b](#irv12455-note-0004){ref-type="fn"}   1 (0.3)
  Current domestic smoking exposure            137 (42.7)                                       114 (37.7)
  Indoor dampness or visible molds             122 (38.0)                                       101 (33.4)

Results expressed in number (percentage) unless stated otherwise.

*P*\<.001.

*P*\<.05.
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![(A) Distribution of FNPS sample collection from our subjects, with two or more FNPS being collected from 320 (99.4%) subjects in 2014 and 295 (95.8%) subjects in 2015; and (B) detection of influenza A and B viruses by surveillance in years 2014 and 2015](IRV-11-319-g001){#irv12455-fig-0001}

3.2. Detection of influenza virus in surveillance samples {#irv12455-sec-0016}
---------------------------------------------------------

Influenza A and B viruses were detected in surveillance samples from 27 to 30 subjects respectively, with median (IQR) viral loads of 918 (99‐14 864) copies/μL and 262 (98‐324 027) copies/μL, and which were similar between preschool and school‐age children (*P*\>.15). Figure [1](#irv12455-fig-0001){ref-type="fig"}B illustrates influenza detection in 2014 and 2015. Influenza B predominated in 2014 and influenza A in 2015 (*P*\<.001). One subject had influenza A and B co‐infection in February 2014, and another subject had influenza A in February 2014 followed by influenza B 4 weeks later. Overall, 36 (11.2%) of 321 subjects had influenza A or B infection in 2014 whereas all 19 (6.3%) of 302 subjects had influenza A infection in 2015.

Six influenza A and 11 influenza B were not typable due to low virus load. For the remaining isolates, seven influenza A were A(H1N1)pdm09 and 14 were H3‐positive whereas among influenza B isolates, all detected in 2014, nine were in Yamagata‐lineage and 10 belonged to Victoria‐lineage. Influenza A (total seven) was typed into four A(H1N1)pdm09 and one A/H3 in 2014 and three A(H1N1)pdm09 and 13 A/H3 in 2015 (*P*=.025). None of these children were reported by parents to be "sick" at the time of FNPS collection. Besides, our nurses did not notice significant respiratory symptoms in these children at the time of FNPS collection. All illness FNPS samples were negative for both influenza A and B.

3.3. Relationship between ILI and subjects' demographic and clinical factors {#irv12455-sec-0017}
----------------------------------------------------------------------------

Table [2](#irv12455-tbl-0002){ref-type="table-wrap"} summarizes the relationship between occurrence of ILI and subjects' personal, clinical, and vaccine factors. Subjects with ILI were younger than those without ILI (*P*\<.001), but ILI was not associated with any environmental or clinical factor. Influenza vaccination at all time points was protective against ILI (*P*=.002‐.022). Logistic regression confirmed such association for influenza vaccination within 3 years (odds ratio 0.49, 95% confidence interval 0.29‐0.81; *P*=.005). None of the other factors enlisted in Table [2](#irv12455-tbl-0002){ref-type="table-wrap"} was associated with mild laboratory‐confirmed influenza detected by surveillance (data not shown).

###### 

Relationship between occurrence of ILI and demographic, environmental, and allergy factors

  Factor                                   ILI (n=99)   No ILI (n=524)   *P* [a](#irv12455-note-0007){ref-type="fn"}
  ---------------------------------------- ------------ ---------------- ---------------------------------------------
  Male                                     55 (55.6)    272 (51.9)       .505
  Age in years, mean±SD                    5.8±2.2      7.6±2.4          \<.001
  Born in Hong Kong                        87 (87.9)    423 (80.7)       .090
  Environmental exposures                                                
  Breastfeeding ever                       60 (60.6)    282 (53.8)       .213
  Current domestic smoking exposure        39 (39.4)    210 (40.1)       .899
  Current maternal smoking                 8 (8.1)      48 (9.2)         .731
  Current dog/cat keeping                  10 (10.1)    43 (8.2)         .535
  Indoor dampness or visible molds         41 (41.1)    180 (34.4)       .178
  Presence of elder brother                24 (24.2)    117 (22.3)       .676
  Presence of elder sister                 25 (25.3)    103 (19.7)       .206
  Allergy phenotypes                                                     
  Wheeze ever                              18 (18.2)    89 (17.0)        .772
  Current wheeze                           12 (12.1)    53 (10.1)        .549
  Asthma ever                              5 (5.1)      34 (6.5)         .588
  Use of asthma medication in past 12 mo   4 (4.0)      13 (2.5)         .329
  Rhinitis ever                            31 (31.3)    188 (35.9)       .383
  Eczema ever                              26 (26.3)    137 (26.1)       .981
  History of influenza vaccination                                       
  Within 3 y                               39 (39.4)    294 (56.1)       .002
  At 25‐36 mo ago                          28 (28.3)    212 (40.5)       .022
  At 13‐24 mo ago                          27 (27.3)    229 (43.7)       .002
  Within 12 mo                             29 (29.3)    237 (45.2)       .003
  Ever received pneumococcal vaccine       50 (50.5)    220 (42.0)       .117

ILI, influenza‐like illness; SD, standard deviation.

Results expressed in number (percentage) unless stated otherwise.

Analyzed by Student\'s *t* test for age and χ^2^ or Fisher\'s exact test for other variables as appropriate.
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3.4. Effectiveness of influenza vaccination {#irv12455-sec-0018}
-------------------------------------------

Sixty‐three (18.9%) subjects who received influenza vaccination within 3 years had either IL‐I or laboratory‐confirmed influenza detected by surveillance, which was significantly lower when compared to 86 (29.7%) children who were not vaccinated (*P*\<.005). Table [3](#irv12455-tbl-0003){ref-type="table-wrap"} illustrates the results for influenza VE in our children. Influenza vaccination was protective against ILI (*P*\<.005) but not mild laboratory‐confirmed influenza when subjects were vaccinated within 3 years or 12 months. Influenza vaccine was moderately protective against ILI with VE varied between 42.1% and 51.9% when subjects were vaccinated at different time points before this study. On the other hand, influenza vaccination could not prevent mild laboratory‐confirmed influenza that was identified by surveillance. Table [4](#irv12455-tbl-0004){ref-type="table-wrap"} provides VE results in different age subgroups. Influenza VE was substantially higher among school‐age than preschool children, with 70.9% vs 34.6% for ILI and 44.0% vs −6.2% for mild influenza infection among those vaccinated within 12 months.

###### 

Influenza vaccine effectiveness (VE) for mild laboratory‐confirmed influenza and influenza‐like illness among all 623 preschool and school‐age children

  Outcome                                               Timing of Vaccination   Vaccinated   Not vaccinated       VE (%)
  ----------------------------------------------------- ----------------------- ------------ -------------------- -------------------
  Mild laboratory‐confirmed influenza by surveillance   Within 3 y              n=333        n=290                17.5 (−39.0‐51.3)
  Positive                                              26 (7.8)                27 (9.3)                          
  Negative                                              307 (92.2)              263 (90.7)                        
  Within 12 mo                                          n=266                   n=357        33.2 (−16.9‐62.2)    
  Positive                                              18 (6.8)                35 (9.8)                          
  Negative                                              248 (93.2)              322 (90.2)                        
  13‐24 mo ago                                          n=256                   n=367        6.4 (−58.8‐44.9)     
  Positive                                              21 (8.2)                32 (8.7)                          
  Negative                                              235 (91.8)              335 (91.3)                        
  25‐36 mo ago                                          n=240                   n=383        −14.6 (−92.2‐31.5)   
  Positive                                              22 (9.2)                31 (8.1)                          
  Negative                                              218 (90.8)              352 (91.9)                        
  Influenza‐like illness                                Within 3 y              n=333        n=290                49.4 (24.0‐66.9)
  With ILI                                              39 (11.7)               60 (20.8)                         
  No ILI                                                294 (88.3)              229 (79.2)                        
  Within 12 mo                                          n=266                   n=357        50.0 (22.4‐68.4)     
  With ILI                                              29 (10.9)               70 (19.6)                         
  No ILI                                                237 (89.1)              287 (80.4)                        
  13‐24 mo ago                                          n=256                   n=367        51.9 (24.5‐70.1)     
  With ILI                                              27 (10.5)               72 (19.6)                         
  No ILI                                                229 (89.5)              295 (80.4)                        
  25‐36 mo ago                                          n=240                   n=383        42.1 (10.5‐63.1)     
  With ILI                                              28 (11.7)               71 (18.5)                         
  No ILI                                                212 (88.3)              312 (81.5)                        

Results expressed in number (percentage) for influenza outcomes and mean (95% confidence interval) for VE.
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###### 

Influenza vaccine effectiveness (VE) in the subgroups of 387 school‐age and 236 preschool children

  Outcome                                               Timing of vaccination   School‐age children   Preschool children                                                     
  ----------------------------------------------------- ----------------------- --------------------- -------------------- ------------------- ------- --------------------- ---------------------
  Mild laboratory‐confirmed influenza by surveillance   Within 3 y              n=210                 n=177                30.4 (−28.6‐62.8)   n=123   n=113                 −19.5 (−208.1‐53.1)
  Positive                                              18 (8.6)                21 (11.9)             9 (7.3)              7 (6.2)                                           
  Negative                                              192 (91.4)              156 (88.1)            114 (92.7)           106 (93.8)                                        
  Within 12 mo                                          n=166                   n=221                 44.0 (−10.1‐72.3)    n=100               n=136   −6.2 (−174.8‐58.8)    
  Positive                                              12 (7.2)                27 (12.2)             7 (7.0)              9 (6.6)                                           
  Negative                                              154 (92.8)              194 (87.8)            93 (93.0)            127 (93.4)                                        
  13‐24 mo ago                                          n=166                   n=221                 18.5 (−51.9‐56.6)    n=90                n=146   −28.4 (−229.2‐49.1)   
  Positive                                              15 (9.0)                24 (10.9)             7 (7.8)              9 (6.2)                                           
  Negative                                              151 (91.0)              197 (89.1)            83 (92.2)            137 (93.8)                                        
  25‐36 mo ago                                          n=165                   n=222                 7.1 (−70.8‐49.6)     n=75                n=161   −73.9(−338.2‐28.5)    
  Positive                                              16 (9.7)                23 (10.4)             7 (9.3)              9 (5.6)                                           
  Negative                                              149 (90.3)              199 (89.6)            68 (90.7)            152 (94.4)                                        
  Influenza‐like illness                                Within 3 y              n=210                 n=177                66.4 (30.3‐84.7)    n=123   n=113                 34.3 (−4.8‐59.8)
  With ILI                                              11 (5.2)                25 (14.1)             28 (22.8)            35 (31.0)                                         
  No ILI                                                199 (94.8)              152 (85.9)            95 (77.2)            78 (69.0)                                         
  Within 12 mo                                          n=166                   n=221                 70.9 (31.4‐88.6)     n=100               n=136   34.6 (−6.7‐61.0)      
  With ILI                                              7 (4.2)                 29 (13.1)             22 (22.0)            41 (30.1)                                         
  No ILI                                                159 (95.8)              192 (86.9)            78 (78.0)            95 (69.9)                                         
  13‐24 mo ago                                          n=166                   n=221                 58.8 (11.4‐81.8)     n=90                n=146   43.9 (4.0‐68.6)       
  With ILI                                              9 (5.4)                 27 (12.2)             18 (20.0)            45 (30.8)                                         
  No ILI                                                157 (94.6)              194 (87.8)            72 (80.0)            101 (69.2)                                        
  25‐36 mo ago                                          n=165                   n=222                 43.7 (−13.9‐72.9)    n=75                n=161   26.7 (−22.7‐57.1)     
  With ILI                                              11 (6.7)                25 (11.3)             17 (22.7)            46 (28.6)                                         
  No ILI                                                154 (93.3)              197 (88.7)            58 (77.3)            115 (71.4)                                        

Results expressed in number (percentage) for influenza outcomes and mean (95% confidence interval) for VE.

John Wiley & Sons, Ltd

4. DISCUSSION {#irv12455-sec-0019}
=============

Mild laboratory‐confirmed influenza in children was common during influenza seasons in 2014 and 2015. Influenza vaccine uptake was 36%‐44% among Hong Kong children, and overall influenza VE was moderate (42%‐52%) for ILI. Influenza vaccination was effective against ILI but not mild infection identified by our surveillance. More importantly, influenza VE was substantially higher for both ILI and mild laboratory‐confirmed influenza in school‐age than preschool children.

The prospective cohort design of this study offers an ideal approach for respiratory virus surveillance. A significant proportion of patients with respiratory viral infections only suffer from mild symptoms.[15](#irv12455-bib-0015){ref-type="ref"}, [16](#irv12455-bib-0016){ref-type="ref"}, [17](#irv12455-bib-0017){ref-type="ref"} Patients with influenza may only have mild cough and rhinorrhea. Our investigative approach detected 104 children with ILI and 55 children with mild laboratory‐confirmed influenza during influenza seasons in 2014‐2015. We acknowledge that some ILI cases were not due to influenza because most of these children had not been tested for influenza. Nonetheless, we believe that these numbers would be a better reflection of the clinical spectrum for influenza infections in children.

Randomized controlled trials demonstrated efficacy of influenza vaccination[4](#irv12455-bib-0004){ref-type="ref"}, [5](#irv12455-bib-0005){ref-type="ref"}, [18](#irv12455-bib-0018){ref-type="ref"}, [19](#irv12455-bib-0019){ref-type="ref"}, [20](#irv12455-bib-0020){ref-type="ref"}, but such findings being obtained in an optimal setting may not be generalizable to the real‐life situation. A systematic review showed low influenza VE (often less than 60%) for subjects risk of severe infection.[21](#irv12455-bib-0021){ref-type="ref"} The Influenza Monitoring Vaccine Effectiveness in Europe project found 43% VE in 2011/12.[4](#irv12455-bib-0004){ref-type="ref"} Multiple confounding factors such as difficulty in matching influenza A antigen for the vaccine strain vs the dominant circulating viruses[22](#irv12455-bib-0022){ref-type="ref"}, suboptimal vaccine uptake, and poor infection control practices influenced influenza VE. This prospective surveillance study was designed in this direction with biweekly surveillance for influenza A and B viruses by molecular methods. Thus, our results supported seasonal influenza vaccine to be an effective public health measure to prevent ILI in local children. Subgroup analyses revealed that influenza vaccination might be more effective against both ILI and mild laboratory‐confirmed influenza in school‐age than preschool children (Table [4](#irv12455-tbl-0004){ref-type="table-wrap"}). Another local study reported age‐specific VE for influenza‐related hospitalization to be higher in children aged 3‐5 years than 6‐17 years (91.4% vs 58.1%) in 2015‐16.[23](#irv12455-bib-0023){ref-type="ref"} However, both this and our studies were limited by small sample size in each age group which led to wide 95% confidence intervals and significant overlap of the VE estimates. Similar findings were observed in a study of 2368 inpatients in Beijing in the 2014‐2015 season[24](#irv12455-bib-0024){ref-type="ref"}, a Japanese surveillance in 2013‐2014[25](#irv12455-bib-0025){ref-type="ref"}, and two US studies in 2013‐2014 and 2014‐2015 seasons[26](#irv12455-bib-0026){ref-type="ref"}, [27](#irv12455-bib-0027){ref-type="ref"}. Our finding supported possible impact of extending the influenza vaccination programs to school‐age children, but further studies are needed to address the cost‐effectiveness of this vaccination strategy.

Our findings of four A(H1N1)pdm09 and one A/H3 in 2014 and three A(H1N1)pdm09 and 13 A/H3 in 2015 among the typable viruses were consistent with local surveillance data of A(H1N1)pdm09 dominance from early January 2014 to early March 2014 and A/H3N2 dominance from late December 2014 to early April 2015 (<http://www.chp.gov.hk/en/sas6/101/110/106.html>). Over 95% of A/H3N2 in 2014/15 season was A/Switzerland/9715293/2013‐like, which was mismatched from A/Texas/50/2012 (H3N2)‐like virus being included in the recommended seasonal vaccine. Our molecular typing assay was designed to detect both of these A/H3N2 strains. All influenza B viruses by our surveillance were detected in 2014, with nine being in B/Yamagata‐lineage and 10 being in B/Victoria‐lineage. Whereas the unpredictability of circulating influenza B was known[28](#irv12455-bib-0028){ref-type="ref"}, our typing results were concordant with local CHP data for B/Yamagata‐lineage dominance in early 2014 and low activity (8.4% of isolates) of influenza B in 2014/2015 winter season.

Our government has included children aged 6 months to 5 years as a priority group in the influenza vaccination subsidy scheme. Nonetheless, a small local study found \<20% uptake rate in preschool children.[7](#irv12455-bib-0007){ref-type="ref"} In this study, 36%‐44% of children received influenza vaccination annually (Table [1](#irv12455-tbl-0001){ref-type="table-wrap"}). Uptake of influenza vaccination was also low among local healthcare workers in the post‐pandemic era.[29](#irv12455-bib-0029){ref-type="ref"} Breaking barriers to accept influenza vaccination should be a public health priority in fighting against influenza outbreaks. Our findings of moderate overall influenza VE for ILI in children aged 2‐12 years together with higher VE against both ILI and mild laboratory‐confirmed influenza among the subgroup of school‐age children may represent an additional strategy where the Government Vaccination Program can be expanded to cover children up to 12 years old.

We found that influenza vaccination was effective against ILI but not mild infection identified by 2‐weekly surveillance during influenza seasons, which was surprising given that all the non‐influenza causes of ILI would reduce the observed strength of influenza VE toward the null. One possible explanation relates to study power that we detected many more patients of ILI (n=99) than mild influenza infection (n=57). On the other hand, influenza‐infected children were reported to have increased susceptibility to co‐infection by other respiratory pathogens, notably pneumococcus and staphylococcus, which increased the severity of their RTIs.[30](#irv12455-bib-0030){ref-type="ref"}, [31](#irv12455-bib-0031){ref-type="ref"}, [32](#irv12455-bib-0032){ref-type="ref"} Thus, it is also possible that influenza vaccination prevented ILI by reducing the children with such co‐infections. Vaccinated and unvaccinated patients with influenza infections may exhibit different health care‐seeking behavior. This study adopted the test‐negative design to define influenza VE as it is less susceptible to bias due to misclassification of infection and to confounding by health care‐seeking behavior relative to traditional case‐control or cohort studies.[14](#irv12455-bib-0014){ref-type="ref"}, [33](#irv12455-bib-0033){ref-type="ref"}

Different studies reported that influenza vaccination lowered subject hospitalization rate by 50%‐66%.[5](#irv12455-bib-0005){ref-type="ref"}, [19](#irv12455-bib-0019){ref-type="ref"}, [20](#irv12455-bib-0020){ref-type="ref"} In our research proposal, we targeted to recruit 560 children with evaluable study outcomes which was based on the assumptions of 40% influenza vaccination coverage, respective influenza attack rates of 13% and 25% among vaccinees and non‐vaccinees, and 30% dropout during the surveillance period. Whereas our cohort of 623 subjects should be sufficient to detect the difference in ILI between vaccinated and non‐vaccinated children, this study might not be sufficiently powered to detect the observed difference in laboratory‐confirmed influenza among our subjects. Another limitation relates to our inability to detect symptomatic moderate‐to‐severe laboratory‐confirmed influenza. Students absent on the days of school visits were not sampled. Because of frequent school visits, our nurses could not arrange home visits for collecting FNPS from children with ILI for influenza testing. For influenza A(H1N1)pdm09 infection, the revised WHO ILI case definition with fever and cough had low sensitivity (36%) but higher positive predictive value (42%) and positive likelihood ratio (13.3) than the other case definitions.[34](#irv12455-bib-0034){ref-type="ref"} In a Taiwanese study, the presence of fever, cough and sneezing had the best specificity (77%) for laboratory‐confirmed influenza.[35](#irv12455-bib-0035){ref-type="ref"} Different ILI case definitions adopted in Europe, USA, and Taiwan had comparable accuracy in sensitivity and specificity, and clinical diagnosis of ILI was useful for providing valuable information for surveillance purpose. This study defined ILI by revised criteria that included other respiratory and constitutional symptoms. It is likely that our patients with ILI had influenza during influenza seasons. Another limitation relates to low participation rates of kindergartens (10/238) and primary schools (5/97), which raised concern if our subjects were recruited by convenience sampling. Nonetheless, we believe our surveillance data were generalizable because these kindergartens and primary schools were identified in sequential random batches from all in our target geographic regions that were registered under the Education Bureau. This study was also limited by the lack of surveillance data for subjects' household and class contacts. Most secondary cases in this surveillance were expected to have minimal influenza symptoms due to low viral load. Unless we collect surveillance samples from subjects' close contacts, we shall miss these secondary cases by only calling them for any ILI symptom.

In conclusion, mild laboratory‐confirmed influenza was common among children during influenza seasons in 2014‐2015. Moderate overall influenza VE was found for ILI, and subgroup analyses suggested higher VE for both ILI and mild laboratory‐confirmed influenza in school‐age children. Whether vaccination prevented influenza transmission within families or classes remained unanswered due to lack of reported secondary cases.
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